Report cover image

Genome Editing/Genome Engineering Market based on by Application (Cell Line Engineering, Genetic Engineering, Drug Discovery, Gene-modified Cell Therapy, Diagnostics, and Other Applications), Technology (CRISPR, TALEN, ZFN, and Other Technologies), and E

Publisher IHR Insights Pvt Limited
Published Jan 03, 2024
Length 130 Pages
SKU # HRI20067137

Description

R&D is the first stage in the market's value chain. These items need extensive research and development. R&D efforts are classified into two categories: in-house and outsourced work. In-house responsibilities are concentrated on crucial processes including basic analysis and electronic interpretation of testing parameters. The primary stakeholders in the gene editing supply chain include prominent firms offering gene editing products and services, SMEs, distributors, and end clients (pharmaceutical & biotechnology corporations, academic & research institutions, and diagnostic companies). The primary market influences are investors/funders.

The prominent players in the global gene editing market are Merck KGaA (Germany), Thermo Fisher Scientific, Inc. (US), GenScript (China), Agilent Technologies (US), PerkinElmer (US), Lonza (Switzerland), Tecan Life Sciences (Switzerland), Sangamo Therapeutics (US), Editas Medicine (US), CRISPR Therapeutics AG (Switzerland), Precision Biosciences (US), Cellectis S.A. (France), Intellia Therapeutics (US), Bluebird Bio, Inc. (US), Regeneron Pharmaceuticals (US), AMSBIO (England), Creative Biogene (US), Synthego Corporation (US), and Beam Therapeutics Inc. (US). Others include Caribou Biosciences, Inc. (US), OriGene Technologies (US), New England Biolabs (US), Inscripta (US), and Mammoth Biosciences (US).

Research Methodology:

After secondary research provided a fundamental understanding of the worldwide Genome Editing/Genome Engineering Market scenario, extensive primary research was carried out. A number of primary interviews were carried out with industry experts from the supply and demand sides, including C- and D-level executives, product managers, and marketing and sales managers of major manufacturers, distributors, and channel partners from tier 1 and tier 2 companies offering Genome Editing/Genome Engineering Market, as well as personnel from academia, research, and CROs. These interviews were conducted across five major regions: North America, Europe, Asia Pacific, and the Rest of the World (Latin America & the Middle East & Africa). Participants from the supply-side and demand-side participated in about 70% and 30% of the primary interviews, respectively. Through the use of questionnaires, emails, online surveys, in-person interviews, and phone interviews, this main data was gathered. The primary participants share is given below:

The segmentation coverage of the study is provided below.

Genome Editing/Genome Engineering Market based on Application
  • Cell line engineering
  • Genetic Engineering
  • Drug Discovery
  • Gene-modified cell therapy and Diagnostics
  • Other Applications
Genome Editing/Genome Engineering Market based on Technology
  • CRISPR
  • TALEN
  • ZFN
  • Other technologies
Genome Editing/Genome Engineering Market based on End User
  • Academics & Government Institutes
  • Biotechnology & Pharma Companies
  • Contract Research Organizations
Genome Editing/Genome Engineering Market based on Geography
  • North America
  • US
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe (RoE)
  • Asia Pacific (APAC)
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific (RoAPAC)
  • Latin America (LATAM)
  • Brazil
  • Argentina
  • Rest of South America
  • Middle East and Africa (MEA)
  • UAE
  • Turkey
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa
The worldwide genome editing market is divided into four sections: application, technology, end user, and geography. The market is further divided by application into cell line engineering, genetic engineering, drug discovery, gene modified cell therapy & diagnostics, and other applications. CRISPR, TALEN, ZFN, and other technologies are classified as CRISPR technologies. End users are classified as academics and government institutes, biotechnology and pharmaceutical businesses, and contract research organisations. The market is divided into four regions: North America, Europe, Asia-Pacific, and Latin America and the Caribbean.

In 2020, the CRISPR category accounted for the greatest proportion of the genome editing market by technology. The simplicity of usage associated with CRISPR, which offers it a major edge over ZFN and TALEN, accounts for a large part of this category. In 2020, pharmaceutical firms held the greatest proportion of the genome editing market. The rising frequency of infectious illnesses and cancer is fueling global research efforts. This will increase demand for genome editing in biotechnology and pharmaceutical businesses.

During the forecast period, North America is expected to account for a sizable portion of the worldwide genome editing market. The region's market is expected to grow in the future, owing to the development of gene therapy in the United States, an increase in the use of genetically modified crops, an increase in the prevalence of infectious diseases and cancer, and the availability of research grants and funding.

Agilent Technologies, CRISPR Therapeutics, Danaher, Eurofins Scientific, Editas Medicine, GenScript, Horizon Discovery Limited, Lonza, Merck, and Thermo Fisher Scientific are among the prominent industry participants mentioned in the study.
  • This report illustrates the most vital attributes of the Genome Editing/Genome Engineering Market, which are driving and providing opportunities.
  • This research gives an in-depth analysis of the Genome Editing/Genome Engineering Market growth on the basis of several segments in the market.
  • This report presents the predictions of the past and present trends of the Genome Editing/Genome Engineering Market.
  • This study also presents the competitive analysis, such as key strategies and capabilities of major players of the Genome Editing/Genome Engineering Market.

Table of Contents

130 Pages
1. Executive Summary
2. Industry Outlook
2.1. Industry Overview
2.2. Industry Trends
3. Market Snapshot
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. Market characteristics
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. Application: Market Size & Analysis
5.1. Overview
5.2. Cell line engineering
5.3. Genetic Engineering
5.4. Drug Discovery
5.5. Gene-modified cell therapy and Diagnostics
5.6. Other Applications
6. Technology: Market Size & Analysis
6.1. Overview
6.2. CRISPR
6.3. TALEN
6.4. ZFN
6.5. Other technologies
7. End User: Market Size & Analysis
7.1. Overview
7.2. Academics & Government Institutes
7.3. Biotechnology & Pharma Companies
7.4. Contract Research Organizations
8. Geography: Market Size & Analysis
8.1. Overview
8.2. North America (U.S., Mexico, Canada)
8.3. Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia, Rest of Europe)
8.4. Asia Pacific (Japan, China, India, Australia, South East Asia, Rest of APAC)
8.5. Latin America (Brazil, Argentina)
8.6. Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East and Africa)
9. Competitive Landscape
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. Vendor Profiles
10.1. GENSCRIPT BIOTECH CORPORATION
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. AGLIENT TECHNOLOGIES, INC.
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. MERCK KGAA
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. EDITAS MEDICINE, INC
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. DANAHER CORPORATION
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. CRISPR THERAPEUTICS AG
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. LONZA GROUP LTD.
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. THERMO FISHER SCIENTIFIC, INC.
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. ORIGENE TECHNOLOGIES
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. EUROFINS SCIENTIFIC
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. Analyst Opinion
12. Annexure
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us